Raymond C Rosen1, Frederick Wu2, Hermann M Behre3, Hartmut Porst4, Eric J H Meuleman5, Mario Maggi6, Javier Romero-Otero7, Juan I Martinez-Salamanca8, Thomas Hugh Jones9, Frans M J Debruyne10, Karl-Heinz Kurth11, Geoff I Hackett12, Richard Quinton13, Peter Stroberg14, Yacov Reisman15, Edoardo S Pescatori16, Antonio Morales17, Lluis Bassas18, Natalio Cruz19, Glenn R Cunningham20, Olivia A Wheaton21. 1. New England Research Institutes, Inc, Watertown, MA, USA. Electronic address: RRosen@neriscience.com. 2. University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Centre for Endocrinology and Diabetes, Andrology Research Unit, Manchester, UK. 3. Martin Luther University Halle-Wittenberg, Center for Reproductive Medicine and Andrology, Halle, Germany. 4. Private Practice of Urology and Andrology, Hamburg, Germany. 5. VU University Medical Center, Amsterdam, The Netherlands. 6. University of Florence, Clinical Physiopathology, Andrology Unit, Florence, Italy. 7. Hospital Universitario 12 de Octubre, Madrid, Comunidad de Madrid, Spain. 8. Hospital Universitario Puerta del Hierro Majadahonda, Madrid, Spain. 9. Barnsley Hospital NHS Foundation Trust, Barnsley, Barnsley, UK. 10. Andros Men's Health Institutes, Arnhem, The Netherlands. 11. Universiteit van Amsterdam, Amsterdam, The Netherlands. 12. Holly Cottage Clinic, Lichfield, UK. 13. Institute of Genetic Medicine, University of Newcastle-upon-Tyne, Newcastle-Upon-Tyne, UK. 14. Department of Surgical and Perioperative Sciences, Urology and Andrology. Umeå university, Umeå, Sweden. 15. Amstelland Hospital Amstelveen, The Netherlands. 16. Hesperia Hospital, Servizio di Andrologia, Modena, Italy. 17. Hospital Carlos Haya, Urology Plaza Hospital Civil s/n Malaga, Malaga, Spain. 18. Fundació Puigvert, Barcelona, Spain. 19. Hospital Universitario Virgen del Rocio, Sevilla, Andalucía, Spain. 20. Baylor College of Medicine, Department of Medicine, Houston, TX, USA. 21. New England Research Institutes, Inc, Watertown, MA, USA.
Abstract
BACKGROUND: The benefits and risks of long-term testosterone administration have been a topic of much scientific and regulatory interest in recent years. AIM: To assess long-term quality of life (QOL) and sexual function benefits of testosterone replacement therapy (TRT) prospectively in a diverse, multinational cohort of men with hypogonadism. METHODS: A multinational patient registry was used to assess long-term changes associated with TRT in middle-age and older men with hypogonadism. Comprehensive evaluations were conducted at 6, 12, 24, and 36 months after enrollment into the registry. OUTCOMES: QOL and sexual function were evaluated by validated measures, including the Aging Males' Symptom (AMS) Scale and the International Index of Erectile Function (IIEF). RESULTS: A total of 999 previously untreated men with hypogonadism were enrolled at 25 European centers, 750 of whom received TRT at at least one visit during the period of observation. Patients on TRT reported rapid and sustained improvements in QOL, with fewer sexual, psychological, and somatic symptoms. Modest improvements in QOL and sexual function, including erectile function, also were noted in RHYME patients not on TRT, although treated patients showed consistently greater benefit over time in all symptom domains compared with untreated patients. AMS total scores for patients on TRT were 32.8 (95% confidence interval = 31.3-34.4) compared with 36.6 (95% confidence interval = 34.8-38.5) for untreated patients (P < .001). Small but significant improvements in IIEF scores over time also were noted with TRT. Approximately 25% of treated and untreated men also used phosphodiesterase type 5 inhibitors, with notable differences in the frequency of phosphodiesterase type 5 inhibitor prescription use according to physician specialty and geographic site location. CLINICAL IMPLICATIONS: TRT-related benefits in QOL and sexual function are well maintained for up to 36 months after initiation of treatment. STRENGTHS AND LIMITATIONS: The major strengths are the large, diverse patient population being treated in multidisciplinary clinical settings. The major limitation is the frequency of switching from one formulation to another. CONCLUSION: Overall, we confirmed the broad and sustained benefits of TRT across major QOL dimensions, including sexual, somatic, and psychological health, which were sustained over 36 months in our treatment cohort. Rosen RC, Wu F, Behre H, et al. Quality of Life and Sexual Function Benefits Effects of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME). J Sex Med 2017;14:1104-1115.
RCT Entities:
BACKGROUND: The benefits and risks of long-term testosterone administration have been a topic of much scientific and regulatory interest in recent years. AIM: To assess long-term quality of life (QOL) and sexual function benefits of testosterone replacement therapy (TRT) prospectively in a diverse, multinational cohort of men with hypogonadism. METHODS: A multinational patient registry was used to assess long-term changes associated with TRT in middle-age and older men with hypogonadism. Comprehensive evaluations were conducted at 6, 12, 24, and 36 months after enrollment into the registry. OUTCOMES: QOL and sexual function were evaluated by validated measures, including the Aging Males' Symptom (AMS) Scale and the International Index of Erectile Function (IIEF). RESULTS: A total of 999 previously untreated men with hypogonadism were enrolled at 25 European centers, 750 of whom received TRT at at least one visit during the period of observation. Patients on TRT reported rapid and sustained improvements in QOL, with fewer sexual, psychological, and somatic symptoms. Modest improvements in QOL and sexual function, including erectile function, also were noted in RHYME patients not on TRT, although treated patients showed consistently greater benefit over time in all symptom domains compared with untreated patients. AMS total scores for patients on TRT were 32.8 (95% confidence interval = 31.3-34.4) compared with 36.6 (95% confidence interval = 34.8-38.5) for untreated patients (P < .001). Small but significant improvements in IIEF scores over time also were noted with TRT. Approximately 25% of treated and untreated men also used phosphodiesterase type 5 inhibitors, with notable differences in the frequency of phosphodiesterase type 5 inhibitor prescription use according to physician specialty and geographic site location. CLINICAL IMPLICATIONS: TRT-related benefits in QOL and sexual function are well maintained for up to 36 months after initiation of treatment. STRENGTHS AND LIMITATIONS: The major strengths are the large, diverse patient population being treated in multidisciplinary clinical settings. The major limitation is the frequency of switching from one formulation to another. CONCLUSION: Overall, we confirmed the broad and sustained benefits of TRT across major QOL dimensions, including sexual, somatic, and psychological health, which were sustained over 36 months in our treatment cohort. Rosen RC, Wu F, Behre H, et al. Quality of Life and Sexual Function Benefits Effects of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME). J Sex Med 2017;14:1104-1115.
Authors: Tyler R McClintock; Marie-Therese I Valovska; Nicollette K Kwon; Alexander P Cole; Wei Jiang; Martin N Kathrins; Naeem Bhojani; George E Haleblian; Tracey Koehlmoos; Adil H Haider; Shehzad Basaria; Quoc-Dien Trinh Journal: World J Urol Date: 2019-03-23 Impact factor: 4.226
Authors: Landon G Vom Steeg; Santosh Dhakal; Yishak A Woldetsadik; Han-Sol Park; Kathleen R Mulka; Emma C Reilly; David J Topham; Sabra L Klein Journal: PLoS Pathog Date: 2020-07-09 Impact factor: 6.823
Authors: Biagio Barone; Luigi Napolitano; Marco Abate; Luigi Cirillo; Pasquale Reccia; Francesco Passaro; Carmine Turco; Simone Morra; Francesco Mastrangelo; Antonio Scarpato; Ugo Amicuzi; Vincenzo Morgera; Lorenzo Romano; Francesco Paolo Calace; Savio Domenico Pandolfo; Luigi De Luca; Achille Aveta; Enrico Sicignano; Massimiliano Trivellato; Gianluca Spena; Carlo D'Alterio; Giovanni Maria Fusco; Raffaele Vitale; Davide Arcaniolo; Felice Crocetto Journal: Int J Mol Sci Date: 2022-03-24 Impact factor: 5.923